Protein arginine methyltransferase 1 (PRMT1), a type-I arginine methyltransferase, has been implicated in diverse cellular events. We have focused on the role of PRMT1 in gliomagenesis. In this study, we showed that PRMT1 expression was up-regulated in glioma tissues and cell lines compared with normal brain tissues. The knock-down of PRMT1 resulted in an arrest in the G1-S phase of the cell cycle, proliferation inhibition and apoptosis induction in four glioma cell lines (T98G, U87MG, U251, and A172). Moreover, an in vivo study confirmed that the tumor growth in nude mouse xenografts was significantly decreased in the RNAi-PRMT1 group. Additionally, we found that the level of the asymmetric dimethylated modification of H4R3, a substrate of PRMT1, was higher in glioma cells than in normal brain tissues and decreased after PRMT1 knock-down. Our data suggest a potential role for PRMT1 as a novel biomarker of and therapeutic target in gliomas. [BMB Reports 2012; 45(8): [470][471][472][473][474][475] 
INTRODUCTION
Protein arginine methylation, a type of posttranslational modification (PTM), has either activating or repressing effects on protein activity, which greatly depends on the substrates modified. Arginine methylation is accomplished by a family of protein arginine methyltransferases (PRMTs) that can transfer a methyl group from S-adenosylmethionine to the guanido nitrogens of arginine residues (1). PRMTs are classified into three distinct types (type I-III) on the basis of the location and the type of monomethylarginine or dimethylarginine they introduce. Protein arginine methyltransferase 1 (PRMT1) is a member of the type-I methyltransferases and results in asymmetric dimethylarginine (ADMA) (2). As reported, PRMTs have important roles in DNA repair, signal transduction and gene expression regulation (3, 4). PRMT1 is the most predominant methyltransferase in mammalian cells and accounts for approximately 85% of cellular PRMT activities (5, 6). PRMT1-knockout mice, generated through gene entrapment, fail to develop beyond E6.5, when the cells of the epiblast begin to differentiate. These results suggest that PRMT1 has a fundamental and pre-requisite role in embryonic development (7). Subsequently, a study on conditional PRMT1-knockout mice showed that several proteins were hypomethylated, and the lack of PRMT1 compromised cell proliferation and DNA damage response signaling (8). Because of the importance of PRMT1, many research groups have studied PRMT1 substrates, the major one being histone H4. PRMT1 specifically dimethylates histone H4 arginine 3 (H4R3diMe) and establishes a scaffold for subsequent histone modifications and chromatin remodeling, which have been implicated in transcriptional regulation (9, 10). Recently, dozens of reports have confirmed that methylation events implicated in disease emergence and progression, including cancers (11). Based on the prevalence of PRMT1 substrates in cells and its predominant enzymatic activity, it is highly probable that PRMT1 is connected with many diseases (12). PRMT1 has been reported to have key roles in breast cancer cell apoptosis and osteosarcoma cell proliferation, and it might be a potential therapeutic target for many types of cancer (8, 13, 14) . Additionally, some substrates methylated by PRMT1 may be directly implicated in many diseases. For example, the level of H4R3diMe was higher in prostate cancer compared to normal tissues and could predict the risk of prostate cancer recurrence (15). Cheung discovered that in mixed-lineage leukemia (MLL), PRMT1 was involved in the expression of critical MLL downstream target genes through regulating H4R3 methylation (16). Gliomas are the most common type of primary tumor in the brain and are rarely curable (17). However, the functional role of PRMT1 in gliomas has not been reported. In our work, we show that PRMT1 is up-regulated in human glioma tissues and cell lines. To elucidate the role of PRMT1 in gliomas, we transfected the Stealth TM RNAi of PRMT1 in vitro and in vivo and detected the role of PRMT1 in glioma cell processes. Furthermore, we examined the effect of knocking down PRMT1 on the dimethylation of H4R3 in glioma cells.
RESULTS

PRMT1 is up-regulated in human glioma tissues and cell lines
To detect the expression pattern of PRMT1 in gliomas, western http://bmbreports.org BMB Reports blotting was performed in 2 normal brain tissues and 17 primary glioma samples. In addition, the total RNA and protein were extracted from two normal brain tissues and four glioma cell lines, and real-time PCR and western blotting were performed to analyze the expression profile of PRMT1. As shown in Fig. 1A , the expression of PRMT1 was increased in more than 76% of glioma samples compared with the two normal brain tissues. In the glioma cell lines, PRMT1 expression was also upregulated (Fig. 1B, 1C) . Furthermore, one grade II glioma patient sample was analyzed with HE staining and immunohistochemistry with a specific PRMT1 antibody (Fig. 1D) .
The tumor area showed a strong positive signal for PRMT1. By contrast, the normal tissue area showed weak staining. These data indicated that PRMT1 expression was elevated in glioma tissues and cells compared with normal brain tissues.
The knockdown of PRMT1 with Stealth TM RNAi inhibited the proliferation of and promoted apoptosis in glioma cells
To examine the role of PRMT1 in glioma cells, we synthesized Stealth TM RNAi duplexes of PRMT1. On the third day after transfection with the RNAi, PRMT1 expression was examined in T98G, U87MG, U251 and A172 cell lines with western blotting. The results showed that the protein level of PRMT1 in the RNAi-PRMT1 group was reduced by at least 70% compared with the RNAi-NC group (Fig. 2A) . To investigate whether the knockdown of PRMT1 affected the cell cycle in glioma cells, flow cytometry analysis was performed. The results showed a different cell cycle profile in the RNAi-PRMT1 group compared with the RNAi-NC group. As shown in Fig. 2B , knocking down PRMT1 with RNAi significantly decreased the cell population in S phase in the four glioma cell lines (U87MG: 18.5 ± 1.03% vs. 24.15 ± 1.28%; T98G: 22.03 ± 4.37% vs. 27.93 ± 3.06%; A172: 15.55 ± 0.78% vs. 21.9 ± 0.99%; and U251: 19.32 ± 0.62% vs. 23.12 ± 0.82%). Additionally, the percentage of cells in G1 phase was higher in glioma cells transfected with PRMT1 RNAi than in the control (U87MG: 69.7 ± 1.62% vs. 64.35 ± 2.10%; T98G: 69.87 ± 1.09% vs. 62.6 ± 0.79%; A172: 78.45 ± 0.62% vs. 71.17 ± 1.89%; and U251: 76.08 ± 1.03% vs. 71.87 ± 1.19%). These results showed that the cell cycle of glioma cells was arrested
